Report Categories
View AllRecent Articles
View All
Crypto Firm Backed by French NBA Star Halts Bitcoin Purchase Plan
The key risks discussed in Liminatus Pharma LIMN earnings LIMN QX Earnings Liminatus Pharma Reports No Revenue Pipeline Focus
ODD ODDITY delivers a strong Q4 2025 EPS beat shares notch a 168 percent gain on positive investor sentiment
OneConstruction ONEG Stock 13D Filings Underperforming 20260422
Transportadora TGS Stock Is It Showing Downtrend Signals 035 20260422
KLA Corp KLAC
Southern Company SO Neutral NearTerm Outlook Amid Modest Earnings Revisions and Steady Revenue Growth
Penske PAG Stock Days To Cover Near Highs 20260420
Oruka Therapeutics ORKA Q4 2025 narrower than expected loss pushes shares up two percent on positive investor sentiment
XSW XSW Software Sector Underperformance Flashes Early Warning Signal for Broader US Equity Markets
Would buying Pearl PDCC stock now make sense Pearl posts 3 EPS miss versus analyst estimates
ConAgra CAG Stock Technical Risk Eye on Rally 20260420
SLNO Soleno Therapeutics tops Q4 2025 EPS estimates by 103 percent shares edge 021 percent lower today
How financially strong is ARB IOT ARBB Pushes Higher 20260501
Why Royalty RMCO business model holds up in any market Momentum Building 20260505
FCF First posts 86 percent Q1 2026 EPS miss with shares notching a small 022 percent gain today
How Summit SSBI prepares for market disruptions
MSDL Morgan beats Q1 estimates by narrow margin but shares decline 115 percent on uncertain outlook
Occidental Petroleum OXY Comparative Performance and Scale Analysis Against Exxon Mobil XOM Post Q1 2026 Earnings Release
IMVT Immunovant beats earnings estimates by 16 but stock slides 5 as investors await revenue clarity
DBI Designer beats earnings estimates by 38 despite revenue decline yet shares fall amid margin concerns
ASML Holding NV ASML UBS Deutsche Bank Lift Price Targets Following Q1 Earnings Beat and Upgraded FullYear Guidance
Trump Departs China After Talks with Xi Implications for Geopolitical Risk and Markets
Goldline Pharmaceutical IPO Allotment Status Today Key Dates GMP and How to Check Allocation
Whats Next for Vanda Pharmaceuticals VNDA at 646 20260514
Cybersecurity Conflicts Escalate The Evolving Battle Between Corporations and Cybercriminals